文献速递传染病防控与疫情报告免疫规划

2型口服脊灰疫苗选择与延迟疫情应对的后果

Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
PubMed 文献 · Vaccine · 2021-05-14

全球脊灰根除倡议面临2型循环疫苗衍生脊灰病毒(cVDPV2)疫情挑战,OPV2停用后疫情未消失。研究使用全球脊灰传播模型分析延迟应对以等待nOPV2的利弊,发现尽快使用现有mOPV2应对可减少疾病负担和传播风险,延迟应对可能显著增加预期病例数。

要点

  • 尽快使用现有mOPV2应对cVDPV2疫情可减少疾病负担和传播风险。
  • 延迟应对以等待nOPV2可能显著增加预期病例数。
  • 各国应尽快使用任何可用OPV2高覆盖率应对疫情,nOPV2可用后再计划使用。

核心结论

  • 尽快使用现有mOPV2应对cVDPV2疫情可减少疾病负担和传播风险。
  • 延迟cVDPV2疫情应对以等待nOPV2可能大幅增加预期病例数并增加重启含OPV2疫苗广泛预防使用的可能性。

研究设计与样本

  • 使用已建立的全球脊灰病毒传播模型,基于COVID-19大流行干扰GPEI活动影响的相关分析。

主要发现

  • 与先前建模一致,尽快使用可用mOPV2应对可减少疫情人群的预期疾病负担并降低疫情病毒传播至其他地区的几率。
  • 延迟cVDPV2疫情应对(如建模为2021年1月至6月无应对)以等待nOPV2,可能在2021-2023年非洲区域增加多达1300例cVDPV2病例。
  • 延迟应对增加触发需要在使用OPV的国家免疫规划中重启含OPV2疫苗广泛预防使用的可能性。

关键数值与推荐

  • 各国应尽快使用任何可用OPV2以高覆盖率轮次应对任何cVDPV2疫情。
  • 计划在nOPV2广泛可用且证据表明其在人群中与mOPV2同样有效但更安全后,根据需要使nOPV2。

临床怎么用

  • cVDPV2疫情应对应优先尽快使用现有OPV2(如mOPV2)实现高覆盖率,而非延迟等待nOPV2。
  • nOPV2可在广泛可用且证据支持其有效性安全性后作为后续选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Global Polio Eradication Initiative (GPEI) faces substantial challenges with managing outbreaks of serotype 2 circulating vaccine-derived polioviruses (cVDPV2s) in 2021. A full five years after the globally coordinated removal of serotype 2 oral poliovirus vaccine (OPV2) from trivalent oral poliovirus vaccine (tOPV) for use in national immunization programs, cVDPV2s did not die out. Since OPV2 cessation, responses to outbreaks caused by cVDPV2s mainly used serotype 2 monovalent OPV (mOPV2) from a stockpile. A novel vaccine developed from a genetically stabilized OPV2 strain (nOPV2) promises to potentially facilitate outbreak response with lower prospective risks, although its availability and properties in the field remain uncertain. Using an established global poliovirus transmission model and building on a related analysis that characterized the impacts of disruptions in GPEI activities caused by the COVID-19 pandemic, we explore the implications of trade-offs associated with delaying outbreak response to avoid using mOPV2 by waiting for nOPV2 availability (or equivalently, delayed responses waiting for national validation of meeting the criteria for nOPV2 initial use). Consistent with prior modeling, responding as quickly as possible with available mOPV2 promises to reduce the expected burden of disease in the outbreak population and to reduce the chances for the outbreak virus to spread to other areas. Delaying cVDPV2 outbreak response (e.g., modeled as no response January-June 2021) to wait for nOPV2 can considerably increase the total expected cases (e.g., by as many as 1,300 cVDPV2 cases in the African region during 2021-2023) and increases the likelihood of triggering the need to restart widescale preventive use of an OPV2-containing vaccine in national immunization programs that use OPV. Countries should respond to any cVDPV2 outbreaks quickly with rounds that achieve high coverage using any available OPV2, and plan to use nOPV2, if needed, once it becomes widely available based on evidence that it is as effective but safer in populations than mOPV2.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kalkowska DA, Pallansch MA, Wassilak SGF, et al. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine. 2021. PMID: 33994237. doi:10.1016/j.vaccine.2021.04.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。